Health insurance allowance possible for Arimidex as second-line treatment for early breast cancer

AstraZeneca Korea said that Arimidex (anastrozole), a typical three-generation adjuvant for the treatment of postmenopausal women with hormone receptor-positive early breast cancer, may be reimbursable following the revised terms for health insurance allowance which took effect on September 9, when the drug is administered as adjuvant treatment.

Under the revised notice of the health ministr...